Significant weight loss with novel CB1-inhibiting antibody
Skye Bioscience has announced preliminary data from a diet-induced obesity (DIO) model in mice, in which its CB1-inhibiting antibody, nimacimab, achieved dose-dependent weight loss of up to 16% compared to vehicle.
Skye developed a DIO model using a transgenic mouse expressing the human CB1 receptor (hCB1R).
Five groups of mice were treated for 35 days with vehicle, 10nmol/kg semaglutide, or nimacimab at 7.5mg/kg, 24mg/kg or 75mg/kg, respectively.
Chris Twitty, Chief Scientific Officer of Skye cautioned that the results are “preliminary”, adding: “The data are very encouraging and provide the first direct evidence supporting our hypothesis that peripheral CB1 inhibition is the primary driver of weight loss, whereas central CB1 inhibition contributes minimally to efficacy yet promotes neuropsychiatric adverse events. With this DIO model developed, we are continuing to assess different parameters and look forward to presenting further preclinical data in the future.”
Key initial findings include:
- A dose-dependent weight loss with nimacimab of 4.5%, 11.4% and 16.0% compared to vehicle
- Significant fat mass loss with lean mass preservation
- Dose-dependent improvement in glucose tolerance
Dr Puneet Arora, Chief Medical Officer of Skye, said: “It is evident from the clinical studies of small molecule CB1 inhibitors that even modest exposure to the brain can cause concerning neuropsychiatric adverse events. We believe that the promising data from these experiments combined with our Phase I data, which showed no significant neuropsychiatric adverse events, places nimacimab as the most promising candidate to realise the therapeutic potential of CB1 inhibition.
“We believe the mechanism of action of nimacimab is complementary to that of incretin mimetics such as GLP-1 receptor agonists. In addition, nimacimab offers the potential of a safe and well-tolerated alternative to the currently approved weight loss drugs.”
Diana Spencer, Senior Digital Content Editor, DDW
